Dr. Tim Darsaut, MD
Claim this profileUniversity of Alberta Hospital
Studies Aneurysm
Studies Brain Aneurysm
8 reported clinical trials
14 drugs studied
Area of expertise
1Aneurysm
Stage IV
Stage I
Stage II
2Brain Aneurysm
Stage IV
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Tim Darsaut, MD is currently running
Comprehensive Aneurysm Management
for Brain Aneurysms
The uncertainty regarding the management of Unruptured Intracranial Aneurysms (UIAs) has not progressed in the last 30 years. The fundamental ethical basis for this study is that physicians should only offer a risky preventive treatment when it has been shown to be beneficial. Before that, such treatment should be offered as an RCT. The CAM trial offers a comprehensive framework, so that all patients confronted with the clinical dilemma can be offered participation. The prinicpal questions to be addressed are : 1. do patients with UIAs, considered for curative treatments, have a better long-term clinical outcome with active treatment or conservative management? 2. when patients are considered ineligible for conservative management, and surgical and endovascular management are both judged reasonable, do patients with UIAs have a better long-term clinical outcome with surgical or endovascular management? The primary hypothesis for patients allocated to at least 2 options, one of which is conservative management is: the 10 year combined neurological morbidity and mortality (mRS\>2) will be reduced from 24% to 16% (beta 80%; alpha 0.048; sample size 961 patients (836 plus 15% losses to FU and cross-overs) with active treatment. This study is designed as a pragmatic, comprehensive way to address the unruptured aneurysm clinical dilemma, combining large simple RCTs whenever patients are judged eligible for more than one management option, or otherwise a registry of each option. All patients with one or more UIAs will be eligible for participation in either a registry or one of the trials. Patients will be followed for 10 years according to a standard of car follow-up schedule. The primary outcome is survival without neurological dependency (mRS\<3) at 10 years. The secondary outcomes are: 1. the incidence of SAH during follow-up and related morbidity and mortality; 2. the morbidity and mortality related to endovascular or surgical treatment of the UIA at one year; 3. overall mortality at 1, 5 and 10 years; 4. overall morbidity (mRS\>2) at 1, 5 and 10 years; 5. length of hospitalization; 6. discharge to location other than home
Recruiting1 award N/A1 criteria
Clipping vs Coiling
for Brain Aneurysm
Intracranial aneurysms located on the middle cerebral artery (MCA) are considered by many surgeons to represent a distinct subgroup of aneurysms for which clipping may still be the best management option. Most MCA aneurysms are accessible, proximal control can readily be secured in case of rupture, and clip application can typically proceed without requiring the dissection of perforating arteries. In comparison, certain anatomic features of MCA aneurysms such as a wide neck, often including a branch artery origin, frequently render endovascular management more difficult. New endovascular devices were and continue to be introduced to address these anatomic difficulties, including stents, flow diverters, and intra-saccular flow disruptors (ISFDs) such as the WEB. Thus, while most aneurysms are increasingly treated with endovascular methods, many MCA aneurysm patients are still managed surgically, but convincing evidence of which management paradigm is best is lacking.
Recruiting1 award N/A4 criteria
More about Tim Darsaut, MD
Clinical Trial Related13 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Tim Darsaut, MD has experience with
- Endovascular Management
- Surgical Management
- Microsurgery
- Endovascular Interventions
- Endovascular Stenting
- Endovascular Coiling
Breakdown of trials Tim Darsaut, MD has run
Aneurysm
Brain Aneurysm
Brain Arteriovenous Malformation
Arteriovenous Malformations
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Tim Darsaut, MD specialize in?
Tim Darsaut, MD focuses on Aneurysm and Brain Aneurysm. In particular, much of their work with Aneurysm has involved Stage IV patients, or patients who are Stage I.
Is Tim Darsaut, MD currently recruiting for clinical trials?
Yes, Tim Darsaut, MD is currently recruiting for 4 clinical trials in Edmonton Alberta. If you're interested in participating, you should apply.
Are there any treatments that Tim Darsaut, MD has studied deeply?
Yes, Tim Darsaut, MD has studied treatments such as Endovascular management, Surgical management, Microsurgery.
What is the best way to schedule an appointment with Tim Darsaut, MD?
Apply for one of the trials that Tim Darsaut, MD is conducting.
What is the office address of Tim Darsaut, MD?
The office of Tim Darsaut, MD is located at: University of Alberta Hospital, Edmonton, Alberta T6G 2R3 Canada. This is the address for their practice at the University of Alberta Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.